Muscle Loss on GLP-1s: What the Body-Composition Data Shows

A weight-loss medication that also melts away muscle is a troubling rumor to run into online. The claim follows GLP-1 medications everywhere they get discussed: semaglutide and tirzepatide burn fat, but they also strip lean tissue, leaving people "skinny fat" after months of injections. The rumor isn't invented out of nothing. It traces back to real body-composition data buried inside a handful of clinical trials. What gets lost between the data and the headline is how much lean mass actually changes compared with fat, and what researchers make of the difference.

What a DEXA scan actually measures

Most weight-loss trials weigh people on a scale and stop there. A smaller number ran a sub-study using DEXA scans, a type of low-dose X-ray imaging that splits body weight into fat mass, lean mass (mostly muscle, along with organs and water), and bone. That split matters because two people can lose the same 20 pounds and end up with very different bodies underneath, depending on how much of that loss came from fat and how much came from muscle.

What the STEP 1 sub-study found

The most-cited body-composition data on semaglutide comes from a DEXA sub-study of STEP 1, one of the trials behind semaglutide's approval for weight management. Researchers scanned 140 of the trial's participants, all of them adults with obesity or overweight, before and after 68 weeks on either weekly semaglutide (2.4 mg) or a placebo, with everyone following the trial's lifestyle program.

People on semaglutide lost 15.0% of their body weight, compared with 3.6% on placebo. Underneath that number: total fat mass dropped 19.3%, and visceral fat, the fat around internal organs that reviews of this literature tie to cardiometabolic risk, dropped 27.4%. Total lean body mass dropped as well, by 9.7%. Because fat came off faster than lean tissue did, the share of body weight made up of lean mass actually rose slightly by the end of the trial, even as the absolute amount of lean tissue went down.

That is the detail that rarely survives a social media summary. Some of the weight lost was lean mass, and the loss was still fat-dominant, with visceral fat down by the largest margin of the three.

Not a problem unique to GLP-1s

Losing some muscle alongside fat is not specific to GLP-1 medications. A 2025 review in the International Journal of Molecular Sciences puts it plainly: weight loss achieved through lifestyle or surgical interventions is often accompanied by decreases in both fat mass and lean mass. Drawing on pooled data across GLP-1 trials, the same review puts the lean-mass share of total weight loss at roughly 20% to 30%, a range that shifts by study population and by how body composition was measured.

Tirzepatide's pivotal trial, SURMOUNT-1, enrolled 2,539 adults and reported mean weight change of 15.0%, 19.5%, and 20.9% across its three doses over 72 weeks, against 3.1% on placebo. That paper reports no DEXA breakdown at all. Any tirzepatide-specific lean-mass figure has to come from a separate sub-analysis rather than the trial's headline results, which is worth remembering whenever one gets quoted without a citation.

What's still unsettled

Whether that lean-mass loss matters day to day, and what to do about it, is where the research thins out. The 2025 review describes resistance training and higher protein intake as opportunities to enhance muscle preservation during treatment with a GLP-1 medication, and then says in the same breath that rigorous trial evidence remains scarce. It points to one six-month prospective study of 200 adults where semaglutide or tirzepatide alongside structured resistance training and protein guidance produced 11% to 13% total weight loss with lean-mass loss limited to roughly 0.63 kg in women and 1.0 kg in men. One prospective study is a signal, not a settled answer, and the review frames it that way.

If you're weighing a GLP-1 program

None of this settles whether a GLP-1 medication is the right choice for any one person. It does make the muscle-loss question a fair one to raise with whoever is prescribing. If you're evaluating a telehealth option, it's worth asking how follow-up works day to day. The MEDGm program page describes follow-up visits every 12 weeks with dose adjustments, which is the kind of scheduled check-in where a change in strength or appetite is worth flagging to a provider. Compounded semaglutide and tirzepatide, the medications a program like this typically offers, are not FDA-approved products in their own right; they're compounded versions of the active ingredient, available only where a licensed provider determines it's appropriate after an evaluation. The program isn't available in Louisiana, where compounded GLP-1 medication for weight loss is prohibited, and it excludes people under 19 in Nebraska.

Reading claims like this one critically

Body-composition claims about GLP-1 medications tend to spread in their most alarming form: the medication eats your muscle. The DEXA data says something more specific and more useful, that a real but minority share of the weight lost is lean tissue, smaller than the fat-mass loss, with visceral fat dropping the most of all. If you want to work through other common GLP-1 claims the same way, source by source, our collection on reading GLP-1 evidence claims critically covers a wider set of them. Anyone comparing telehealth options for a GLP-1 prescription can review current plans and pricing on the MEDGm program page as well.

Whatever program someone chooses, the body-composition data is a reason to raise the question up front rather than after months of injections. It is worth noting that the trials above studied FDA-approved products, and that a compounded preparation is not the product those trials measured, so the published body-composition numbers describe the studied drugs rather than any particular compounded version of them.

Sources

• Wilding et al., exploratory body-composition sub-study of STEP 1, Journal of the Endocrine Society, 2021, https://academic.oup.com/jes/article/5/Supplement_1/A16/6240360: 140 of the STEP 1 trial's adults with obesity or overweight (95 semaglutide, 45 placebo), semaglutide 2.4 mg weekly vs. placebo, DEXA sub-study, 68 weeks; total body weight -15.0% vs. -3.6%, total fat mass -19.3%, regional visceral fat -27.4%, total lean body mass -9.7%, with lean mass as a proportion of total body mass up 3.0 percentage points; limitation: a sub-study of 140 of the trial's 1,961 participants, no imputation for missing body-composition data, industry-funded.
• Chrysavgis et al., "The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition," International Journal of Molecular Sciences, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12733374/: narrative review pooling GLP-1 trial body-composition data; lean tissue typically 20-30% of total weight reduction across trials; weight loss from lifestyle or surgical interventions is also accompanied by decreases in both fat and lean mass; resistance training and higher protein intake described as opportunities to enhance muscle preservation while "rigorous trial evidence remains scarce"; limitation: a review synthesizing heterogeneous trials with different populations, durations, and measurement methods, not a single controlled study.
• Jastreboff et al., SURMOUNT-1, New England Journal of Medicine, 2022 (PubMed record, DOI 10.1056/NEJMoa2206038), https://pubmed.ncbi.nlm.nih.gov/35658024/: 2,539 adults with a BMI of 30 or more, or 27 or more plus a weight-related complication, diabetes excluded; tirzepatide 5, 10, or 15 mg weekly vs. placebo, including a 20-week dose-escalation period; 72 weeks; mean weight change -15.0%, -19.5%, and -20.9% by dose vs. -3.1% on placebo; limitation: reports no DEXA or lean-mass data, so a tirzepatide-specific lean-mass figure requires a separate body-composition sub-analysis, and none is cited here for that reason.

Educational content only. Not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, changing, or stopping any medication, peptide, or supplement.